BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co Operating Cash Flow

The Operating Cash Flow of BrightGene Bio-Medical Technology Co (688166.SS) as of Nov 22, 2026 is 325.19 M CNY. In the previous year, Operating Cash Flow was 245.56 M CNY — a change of 32.43% (higher).

Operating Cash Flow

325.19 MCNY

YoY

32.43%

Last updated:

Operating Cash Flow of BrightGene Bio-Medical Technology Co is 2025 325.19 M CNY. Operating Cash Flow of BrightGene Bio-Medical Technology Co was 2024 245.56 M CNY. It decreases by 32.43% higher compared to the previous year.

The BrightGene Bio-Medical Technology Co Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
63.99 M CNY
Jan 1, 2019
61.33 M CNY
Jan 1, 2020
155.43 M CNY
Jan 1, 2021
176.08 M CNY
Jan 1, 2022
311.26 M CNY
Jan 1, 2023
194.77 M CNY
Jan 1, 2024
245.56 M CNY
Jan 1, 2025
325.19 M CNY
The BrightGene Bio-Medical Technology Co Operating Cash Flow history
YEAROperating Cash FlowYoY
325.19 MCNY+32.43%
245.56 MCNY+26.08%
194.77 MCNY-37.43%
311.26 MCNY+76.78%
176.08 MCNY+13.28%
155.43 MCNY+153.42%
61.33 MCNY-4.15%
63.99 MCNY+78.90%
35.77 MCNY+20.29%
29.73 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

Operating Cash Flow of BrightGene Bio-Medical Technology Co is 325.19 M CNY in 2025.

Operating Cash Flow of BrightGene Bio-Medical Technology Co changed from 245.56 M CNY to 325.19 M CNY, representing a 32.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's BrightGene Bio-Medical Technology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BrightGene Bio-Medical Technology Co

All Key Metrics — BrightGene Bio-Medical Technology Co